The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection
Journal of Thrombosis and Thrombolysis · 2025
DOI: 10.1007/s11239-025-03096-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Freddy Frost und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpoo…. Hauptthemen laut MEDLINE: COVID-19, Anticoagulants, COVID-19 Drug Treatment, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb- Pfizer alliance, Bristol Myers Squibb– Pfizer alliance.
Abstract (Originalsprache)
Long COVID (LC) or post-acute sequelae of SARS-CoV-2 infection (PASC) is defined as ongoing, relapsing or new symptoms/conditions persisting after an acute COVID-19 infection. Given the potential role of oral anticoagulants (OAC) in treating thrombotic sequelae of LC/PASC, we investigated whether prevalent OAC use at the time of acute COVID-19 infection was associated with reduced development of LC/PASC. Retrospective cohort study within the TriNetx network. The primary cohort was defined as adults with a confirmed diagnosis of COVID-19. We defined OAC users as those who had received OACs (either direct-acting OACs [DOACs] or vitamin K antagonists [VKA]) in the preceding 3-months and non-users as those without OAC use within the previous 12-months. The primary outcome was a composite of 9 features associated with LC/PASC We identified 38,409 DOAC users, 19,243 VKA users, and 2,329,771 non-OAC users with acute COVID-19 infection. After successful propensity score matching (PSM), we found an increased risk of LC/PASC features in those receiving DOAC compared to non-OAC (HR [95% CI] 1.50 [1.35 to 1.68], p < 0.0001), and in VKA users compared to non-OACs (HR [95% CI] 1.98 [1.78 to 2.20], p < 0.0001), while DOAC users were at reduced risk compared to VKA users (HR [95% CI] 0.71 [0.62 to 0.81], p < 0.0001). We found no evidence that prevalent OAC at the time of acute COVID-19 infection was associated with reduced risk of LC/PASC. Further work is needed to understand whether there is a role for OAC therapy in the management of LC/PASC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
- Faculty of Nursing, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB- Arrixaca), CIBERCV, Murcia, Spain.
- Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. gregory.lip@liverpool.ac.uk.
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. gregory.lip@liverpool.ac.uk.
Förderung
- Bristol Myers Squibb- Pfizer alliance
- Bristol Myers Squibb– Pfizer alliance
Zitieren
APA
Frost, F., Rivera-Caravaca, J. M., & Lip, G. Y. H. (2025). The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03096-0
Vancouver
Frost F, Rivera-Caravaca JM, Lip GYH. The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03096-0
BibTeX
@article{Frost2025,
author = {Frost, Freddy and Rivera-Caravaca, José Miguel and Lip, Gregory Y H},
title = {The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2025},
doi = {10.1007/s11239-025-03096-0}
}
EUVIMED